Infliximab in patients with systemic vasculitis that is difficult to treat: Poor outcome and significant adverse effects [6]

Annals of the Rheumatic Diseases

Volumn 66, Issue 4, 2007, Pages 564-565

  Sangle, Shirish R ^a   Hughes, Graham R V ^a   D'Cruz, David P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ANEMIA; BEHCET DISEASE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FATIGUE; FERRITIN BLOOD LEVEL; HEARING IMPAIRMENT; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; LEUKOPENIA; LUPUS LIKE SYNDROME; PRIORITY JOURNAL; SCLERITIS; SIDE EFFECT; SYSTEMIC VASCULITIS; TRACHEA STENOSIS; TREATMENT OUTCOME; VASCULITIS; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 34147217340     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.065623     Document Type: Letter

References (8)

1. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
2. Bacon PA. Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects. Curr Opin Rheumatol 2005;17:49-55.
3. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002;41:1303-7.
4. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J. Prospective study of TNF alfa blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
5. Booth AD, Jayne DR, Kharabanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109:1718-23.
6. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
7. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
8. Jayne D. What place for the new biologies in the treatment of necrotising vasculitis. Clin Exp Rheumatol 2006;24:S1-5.